Visual Abstract
The objective of this retrospective, observational study was to compare 6- and 12-month (mo) adherence and persistence among dulaglutide (DU) vs. matched semaglutide (SEMA) initiators using real-world administrative claims data from the IBM MarketScan Databases. Adult patients (pts) with T2D newly initiating DU or SEMA between January 2018-January 2020 (index date=earliest fill date), without evidence of GLP-1 RA use, pregnancy, gestational diabetes, or bariatric surgery in the 6-mo baseline period, and with continuous enrollment in the 6-mo baseline and 6- or 12-mo follow-up periods were included. DU initiators were propensity-score matched 1:1 to SEMA initiators for each 6- and 12-mo follow-up (26,284 and 13,837 pairs, respectively). Baseline characteristics were balanced with mean age 53 years and 50% females. More DU pts were adherent than SEMA pts (6mo:63% vs. 48%, 12mo: 54% vs. 43%, p values<0.001). More DU pts were persistent on therapy compared to SEMA pts (6mo: 72% vs. 62%, 12mo: 56% vs. 45%, p values<0.001) and had more mean persistent days (6mo: 145 vs. 132, 12mo: 254 vs. 221, p values<0.001). Among pts who escalated and remained on a higher dose of index drug, most were adherent at 6 mos (DU 83% vs. SEMA 75%) and 12 mos (DU 76% vs. SEMA 72%). At both 6 and 12 mos, DU initiators had significantly higher adherence and greater persistence on their therapy than SEMA initiators.
R. Mody: Employee; Self; Eli Lilly and Company. J. Manjelievskaia: Employee; Self; IBM Watson Health, Research Support; Self; Eli Lilly and Company. M. Yu: Employee; Self; Lilly Diabetes, Employee; Spouse/Partner; LifeLabs, Stock/Shareholder; Self; Lilly Diabetes, Stock/Shareholder; Spouse/Partner; Lilly Diabetes. E. H. Marchlewicz: Research Support; Self; Eli Lilly and Company. R. Malik: Employee; Self; Eli Lilly and Company. N. Zimmerman: Consultant; Self; Eli Lilly and Company, Employee; Self; IBM Watson Health. D. E. Irwin: Employee; Self; IBM Watson Health.
